FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009817344> ?p ?o ?g. }

• W2009817344 endingPage "462" @default.
• W2009817344 startingPage "455" @default.
• W2009817344 abstract "BackgroundThymic stromal lymphopoietin (TSLP) pathway blockade is a potential strategy for asthma treatment because the main activities of TSLP are activation of myeloid dendritic cells (mDCs) and modulation of cytokine production by mast cells. TSLP-activated mDCs prime the differentiation of naive T cells into inflammatory TH2 cells.ObjectiveWe sought to investigate mechanisms underlying the development of allergic lung inflammation in cynomolgus monkeys using gene expression profiling and to assess the effect of thymic stromal lymphopoietin receptor (TSLPR) blockade in this model.MethodsAn mAb against human TSLPR was generated and confirmed to be cross-reactive to cynomolgus monkey. Animals were dosed weekly with either vehicle or anti–TSLPR mAb for 6 weeks, and their responses to allergen challenge at baseline, week 2, and week 6 were assessed.ResultsAfter 6 weeks of treatment, anti-TSLPR mAb–treated animals showed reduced bronchoalveolar lavage (BAL) fluid eosinophil counts, reduced airway resistance in response to allergen challenge, and reduced IL-13 cytokine levels in BAL fluid compared with values seen in vehicle-treated animals. Expression profiling of BAL fluid cells collected before and after challenge showed a group of genes upregulated by allergen challenge that strongly overlapped with 11 genes upregulated in dendritic cells (DCs) when in vitro stimulated by TSLP (TSLP-DC gene signature). The number of genes differentially expressed in response to challenge was reduced in antibody-treated animals after 6 weeks relative to vehicle-treated animals. Expression of the TSLP-DC gene signature was also significantly reduced in antibody-treated animals.ConclusionThese results demonstrate promising efficacy for TSLPR blockade in an allergic lung inflammation model in which TSLP activation of mDCs might play a key role. Thymic stromal lymphopoietin (TSLP) pathway blockade is a potential strategy for asthma treatment because the main activities of TSLP are activation of myeloid dendritic cells (mDCs) and modulation of cytokine production by mast cells. TSLP-activated mDCs prime the differentiation of naive T cells into inflammatory TH2 cells. We sought to investigate mechanisms underlying the development of allergic lung inflammation in cynomolgus monkeys using gene expression profiling and to assess the effect of thymic stromal lymphopoietin receptor (TSLPR) blockade in this model. An mAb against human TSLPR was generated and confirmed to be cross-reactive to cynomolgus monkey. Animals were dosed weekly with either vehicle or anti–TSLPR mAb for 6 weeks, and their responses to allergen challenge at baseline, week 2, and week 6 were assessed. After 6 weeks of treatment, anti-TSLPR mAb–treated animals showed reduced bronchoalveolar lavage (BAL) fluid eosinophil counts, reduced airway resistance in response to allergen challenge, and reduced IL-13 cytokine levels in BAL fluid compared with values seen in vehicle-treated animals. Expression profiling of BAL fluid cells collected before and after challenge showed a group of genes upregulated by allergen challenge that strongly overlapped with 11 genes upregulated in dendritic cells (DCs) when in vitro stimulated by TSLP (TSLP-DC gene signature). The number of genes differentially expressed in response to challenge was reduced in antibody-treated animals after 6 weeks relative to vehicle-treated animals. Expression of the TSLP-DC gene signature was also significantly reduced in antibody-treated animals. These results demonstrate promising efficacy for TSLPR blockade in an allergic lung inflammation model in which TSLP activation of mDCs might play a key role." @default.
• W2009817344 created "2016-06-24" @default.
• W2009817344 creator A5003934063 @default.
• W2009817344 creator A5007947406 @default.
• W2009817344 creator A5011932678 @default.
• W2009817344 creator A5016574592 @default.
• W2009817344 creator A5021818711 @default.
• W2009817344 creator A5029631003 @default.
• W2009817344 creator A5035849162 @default.
• W2009817344 creator A5047101288 @default.
• W2009817344 creator A5048420468 @default.
• W2009817344 creator A5051348384 @default.
• W2009817344 creator A5055050909 @default.
• W2009817344 creator A5069332915 @default.
• W2009817344 creator A5071672663 @default.
• W2009817344 creator A5080902157 @default.
• W2009817344 creator A5085232884 @default.
• W2009817344 creator A5086450395 @default.
• W2009817344 creator A5087892949 @default.
• W2009817344 creator A5090500679 @default.
• W2009817344 date "2013-08-01" @default.
• W2009817344 modified "2023-09-23" @default.
• W2009817344 title "Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma" @default.
• W2009817344 cites W1558665965 @default.
• W2009817344 cites W1625157530 @default.
• W2009817344 cites W1630159102 @default.
• W2009817344 cites W1968204922 @default.
• W2009817344 cites W1974700408 @default.
• W2009817344 cites W1975436922 @default.
• W2009817344 cites W1975438745 @default.
• W2009817344 cites W1979026253 @default.
• W2009817344 cites W1996970629 @default.
• W2009817344 cites W2011998167 @default.
• W2009817344 cites W2038011147 @default.
• W2009817344 cites W2054739576 @default.
• W2009817344 cites W2068870295 @default.
• W2009817344 cites W2089321729 @default.
• W2009817344 cites W2105680170 @default.
• W2009817344 cites W2126934332 @default.
• W2009817344 cites W2128569175 @default.
• W2009817344 cites W2130410032 @default.
• W2009817344 cites W2131268464 @default.
• W2009817344 cites W2135790224 @default.
• W2009817344 cites W2158206794 @default.
• W2009817344 cites W2159707944 @default.
• W2009817344 cites W2162803006 @default.
• W2009817344 cites W2164692566 @default.
• W2009817344 cites W2170948066 @default.
• W2009817344 cites W86681478 @default.
• W2009817344 doi "https://doi.org/10.1016/j.jaci.2013.05.011" @default.
• W2009817344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23810153" @default.
• W2009817344 hasPublicationYear "2013" @default.
• W2009817344 type Work @default.
• W2009817344 sameAs 2009817344 @default.
• W2009817344 citedByCount "49" @default.
• W2009817344 countsByYear W20098173442014 @default.
• W2009817344 countsByYear W20098173442015 @default.
• W2009817344 countsByYear W20098173442016 @default.
• W2009817344 countsByYear W20098173442017 @default.
• W2009817344 countsByYear W20098173442018 @default.
• W2009817344 countsByYear W20098173442019 @default.
• W2009817344 countsByYear W20098173442020 @default.
• W2009817344 countsByYear W20098173442021 @default.
• W2009817344 countsByYear W20098173442022 @default.
• W2009817344 countsByYear W20098173442023 @default.
• W2009817344 crossrefType "journal-article" @default.
• W2009817344 hasAuthorship W2009817344A5003934063 @default.
• W2009817344 hasAuthorship W2009817344A5007947406 @default.
• W2009817344 hasAuthorship W2009817344A5011932678 @default.
• W2009817344 hasAuthorship W2009817344A5016574592 @default.
• W2009817344 hasAuthorship W2009817344A5021818711 @default.
• W2009817344 hasAuthorship W2009817344A5029631003 @default.
• W2009817344 hasAuthorship W2009817344A5035849162 @default.
• W2009817344 hasAuthorship W2009817344A5047101288 @default.
• W2009817344 hasAuthorship W2009817344A5048420468 @default.
• W2009817344 hasAuthorship W2009817344A5051348384 @default.
• W2009817344 hasAuthorship W2009817344A5055050909 @default.
• W2009817344 hasAuthorship W2009817344A5069332915 @default.
• W2009817344 hasAuthorship W2009817344A5071672663 @default.
• W2009817344 hasAuthorship W2009817344A5080902157 @default.
• W2009817344 hasAuthorship W2009817344A5085232884 @default.
• W2009817344 hasAuthorship W2009817344A5086450395 @default.
• W2009817344 hasAuthorship W2009817344A5087892949 @default.
• W2009817344 hasAuthorship W2009817344A5090500679 @default.
• W2009817344 hasConcept C104317684 @default.
• W2009817344 hasConcept C126322002 @default.
• W2009817344 hasConcept C127561419 @default.
• W2009817344 hasConcept C203014093 @default.
• W2009817344 hasConcept C2776042228 @default.
• W2009817344 hasConcept C2776914184 @default.
• W2009817344 hasConcept C2777037409 @default.
• W2009817344 hasConcept C2777714996 @default.
• W2009817344 hasConcept C2777961210 @default.
• W2009817344 hasConcept C2778070265 @default.
• W2009817344 hasConcept C2778690821 @default.
• W2009817344 hasConcept C2779675166 @default.
• W2009817344 hasConcept C55493867 @default.
• W2009817344 hasConcept C71924100 @default.

• next